Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 114.59Cr 100Cr 93Cr 85Cr 160.95Cr 11TCr 163.75Cr 1.1TCr 429.39Cr 5.45TCr 430.44Cr 420.9Cr 18TCr P/E 2026 *
-7.59x
P/E 2027 * -6.88x
Enterprise Value 114.59Cr 100Cr 93Cr 85Cr 160.95Cr 11TCr 163.75Cr 1.1TCr 429.39Cr 5.45TCr 430.44Cr 420.9Cr 18TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 day-1.72%
1 week-8.49%
Current month-0.63%
1 month+0.82%
3 months+14.23%
Current year+34.47%
1 week 10.45
Extreme 10.45
12.13
1 month 10.29
Extreme 10.29
12.57
Current year 7.23
Extreme 7.23
14.25
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
26.7
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 07/05/2018
Director of Finance/CFO 52 01/09/2019
Chief Tech/Sci/R&D Officer - 18/08/2025
Director TitleAgeSince
Chairman 68 07/03/2018
Director/Board Member 47 07/05/2018
Director/Board Member 62 01/02/2020
Date Insider Type Main position Quantity % Market Cap.
24/07/26 Fiscal year

Founder

20,100 0.0194%
06/07/26 Sell

Founder

-300 0.0003%
24/02/26 Fiscal year

Chief Financial Officer

1,56,000 0.1602%
Change 5-day change 1-year change 3-year change Capi.($)
-4.65%-8.49%+12.88%+39.77% 114.59Cr
+0.05%+2.80%+38.17%+74.12% 5.65TCr
-3.06%-8.56%+22.91%+58.73% 5.36TCr
+2.64%+3.03%-14.71%-12.00% 2.29TCr
-1.05%-7.19%-12.62%+338.85% 2.14TCr
+0.15%-0.77%+23.76%-11.52% 2.03TCr
-0.67%-3.25%+30.55%-29.84% 1.76TCr
-1.45%-7.24%+17.67%+563.14% 1.47TCr
+9.91%+2.64%+188.84%+326.19% 1.35TCr
+2.77%-3.51%+46.29%+159.39% 1.33TCr
Average +0.76%-2.54%+35.38%+150.68% 2.35TCr
Weighted average by Cap. +0.11%-1.73%+30.83%+121.00%

Financials

2026 *2027 *
Net sales - -
Net income -16Cr -14Cr -13Cr -12Cr -22Cr -1.49TCr -22Cr -149.5Cr -59Cr -742.74Cr -59Cr -57Cr -2.45TCr -19Cr -16Cr -15Cr -14Cr -27Cr -1.81TCr -27Cr -181.43Cr -71Cr -901.37Cr -71Cr -70Cr -2.97TCr
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
104
Date Price Change Volume
03/26/03 $10.48 -5.33% 9,63,188
31/26/31 $11.07 -4.90% 12,38,822
30/26/30 $11.64 +3.19% 18,74,846
29/26/29 $11.28 -5.29% 18,67,926
28/26/28 $11.91 -0.92% 11,44,802
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
11.07USD
Average target price
20.69USD
Spread / Average Target
+86.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock